Results
1 -
9 of
9
(Click
here to explore results)
- Histone deacetylase inhibitors for the treatment of cancer stem cells. M. Dvorakova, T. Vanek
, Med. Chem. Commun.
, 2016
, 7
, 2217
- Total synthesis and biological evaluation of histone deacetylase inhibitor WF-3161. Michael Kohr, Niklas Papenkordt, Manfred Jung, Uli Kazmaier
, Org. Biomol. Chem.
, 2023
, 21
, 4382
- Chimerically designed HDAC- and tyrosine kinase inhibitors. A series of erlotinib hybrids as dual-selective inhibitors of EGFR, HER2 and histone deacetylases. Thomas Beckers, Siavosh Mahboobi, Andreas Sellmer, Matthias Winkler, Emerich Eichhorn, Herwig Pongratz, Thomas Maier, Thomas Ciossek, Thomas Baer, Gerhard Kelter, Heinz-Herbert Fiebig, Mathias Schmidt
, Med. Chem. Commun.
, 2012
, 3
, 829
- Small molecule inhibitors in pancreatic cancer. Jufeng Sun, Cecilia C. Russell, Christopher J. Scarlett, Adam McCluskey
, RSC Med. Chem.
, 2020
, 11
, 164
- Small-molecular modulators of cancer-associated epigenetic mechanisms. Yukihiro Itoh, Takayoshi Suzuki, Naoki Miyata
, Mol. BioSyst.
, 2013
, 9
, 873
- MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives. Teja Ram, Ankit Kumar Singh, Adarsh Kumar, Harshwardhan Singh, Prateek Pathak, Maria Grishina, Habibullah Khalilullah, Mariusz Jaremko, Abdul-Hamid Emwas, Amita Verma, Pradeep Kumar
, RSC Med. Chem.
, 2023
, 14
, 1837
- Synthesis and antiproliferative assay of triazolyl-2,2-dimethyl-3-phenylpropanoates as potential HDAC inhibitors. Samir El-Rayes, Gomaa M. S., Abouelmagd A., Walid Fathalla, Ibrahim. A. I. Ali
, RSC Adv.
, 2019
, 9
, 13896
- Development of second generation epigenetic agents. Philip Jones
, Med. Chem. Commun.
, 2012
, 3
, 135
- Developing novel non-hydroxamate histone deacetylase
inhibitors: the chelidamic warhead. Sergio Valente, Mariarosaria Conte, Maria Tardugno, Angela Nebbioso, Gabriella Tinari, Lucia Altucci, Antonello Mai
, Med. Chem. Commun.
, 2012
, 3
, 298